JP2021513860A5 - - Google Patents
Info
- Publication number
- JP2021513860A5 JP2021513860A5 JP2020544206A JP2020544206A JP2021513860A5 JP 2021513860 A5 JP2021513860 A5 JP 2021513860A5 JP 2020544206 A JP2020544206 A JP 2020544206A JP 2020544206 A JP2020544206 A JP 2020544206A JP 2021513860 A5 JP2021513860 A5 JP 2021513860A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- uapc
- immune cells
- immune
- derived
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062460A JP7837068B2 (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633587P | 2018-02-21 | 2018-02-21 | |
| US62/633,587 | 2018-02-21 | ||
| PCT/US2019/018989 WO2019165097A1 (en) | 2018-02-21 | 2019-02-21 | Universal antigen presenting cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062460A Division JP7837068B2 (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513860A JP2021513860A (ja) | 2021-06-03 |
| JP2021513860A5 true JP2021513860A5 (https=) | 2022-03-01 |
| JPWO2019165097A5 JPWO2019165097A5 (https=) | 2022-03-01 |
| JP7591405B2 JP7591405B2 (ja) | 2024-11-28 |
Family
ID=67686940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544206A Active JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
| JP2024062460A Active JP7837068B2 (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062460A Active JP7837068B2 (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20200390815A1 (https=) |
| EP (1) | EP3755347B1 (https=) |
| JP (2) | JP7591405B2 (https=) |
| KR (1) | KR20200123459A (https=) |
| CN (1) | CN112292137A (https=) |
| AU (1) | AU2019226021B2 (https=) |
| BR (1) | BR112020016876A2 (https=) |
| CA (1) | CA3091671A1 (https=) |
| DK (1) | DK3755347T3 (https=) |
| ES (1) | ES3035716T3 (https=) |
| FI (1) | FI3755347T3 (https=) |
| MX (1) | MX2020008801A (https=) |
| MY (1) | MY210248A (https=) |
| PL (1) | PL3755347T3 (https=) |
| PT (1) | PT3755347T (https=) |
| SG (1) | SG11202008008UA (https=) |
| TW (1) | TWI899050B (https=) |
| WO (1) | WO2019165097A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| MX2021006393A (es) * | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
| WO2020205359A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Methods for production of car-nk cells and use thereof |
| JP2022546101A (ja) * | 2019-09-01 | 2022-11-02 | エクスマ バイオテック コーポレイション | リンパ球の改変および送達のための方法および組成物 |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| TW202300520A (zh) * | 2021-05-19 | 2023-01-01 | 大陸商上海詩健生物科技有限公司 | 特異性識別baff-r的嵌合抗原受體分子及其應用 |
| CN113832190A (zh) * | 2021-09-24 | 2021-12-24 | 中海峡(福建)细胞生物科技有限公司 | 一种利用基因工程修饰的滋养细胞的制备方法及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| US5939281A (en) | 1996-09-16 | 1999-08-17 | Case Western Reserve University | Detecting alloreactivity |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
| AU2005250408B2 (en) * | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| PT1879599E (pt) | 2005-04-20 | 2014-01-23 | Hutchinson Fred Cancer Res | Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos |
| US9121008B2 (en) * | 2005-08-31 | 2015-09-01 | University Of Utah Research Foundation | Development of natural killer cells and functional natural killer cell lines |
| US10611818B2 (en) * | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US9062287B2 (en) * | 2009-09-11 | 2015-06-23 | Takara Bio Inc. | Process for production of natural killer cells |
| EP2841563B1 (en) * | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| EP3578201B1 (en) * | 2012-06-28 | 2023-04-19 | University Of Central Florida Research Foundation Incorporated | Methods and compositions for natural killer cells |
| JP6775426B2 (ja) * | 2014-03-07 | 2020-10-28 | エメルセル エスエーエス | 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途 |
| WO2015154012A1 (en) * | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| EP3223856B1 (en) * | 2014-10-27 | 2025-09-24 | University of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| CA2965521A1 (en) * | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| US11154572B2 (en) * | 2015-06-05 | 2021-10-26 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| EP3138905A1 (en) * | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| CN115404196A (zh) * | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| CN109844099B (zh) * | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| MX2021006393A (es) * | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
-
2019
- 2019-02-21 PT PT197576705T patent/PT3755347T/pt unknown
- 2019-02-21 MX MX2020008801A patent/MX2020008801A/es unknown
- 2019-02-21 WO PCT/US2019/018989 patent/WO2019165097A1/en not_active Ceased
- 2019-02-21 TW TW108105835A patent/TWI899050B/zh active
- 2019-02-21 MY MYPI2020004259A patent/MY210248A/en unknown
- 2019-02-21 JP JP2020544206A patent/JP7591405B2/ja active Active
- 2019-02-21 FI FIEP19757670.5T patent/FI3755347T3/fi active
- 2019-02-21 US US16/970,930 patent/US20200390815A1/en active Pending
- 2019-02-21 EP EP19757670.5A patent/EP3755347B1/en active Active
- 2019-02-21 KR KR1020207027108A patent/KR20200123459A/ko not_active Ceased
- 2019-02-21 DK DK19757670.5T patent/DK3755347T3/da active
- 2019-02-21 BR BR112020016876-9A patent/BR112020016876A2/pt unknown
- 2019-02-21 ES ES19757670T patent/ES3035716T3/es active Active
- 2019-02-21 CN CN201980021995.0A patent/CN112292137A/zh active Pending
- 2019-02-21 SG SG11202008008UA patent/SG11202008008UA/en unknown
- 2019-02-21 AU AU2019226021A patent/AU2019226021B2/en active Active
- 2019-02-21 PL PL19757670.5T patent/PL3755347T3/pl unknown
- 2019-02-21 CA CA3091671A patent/CA3091671A1/en active Pending
-
2024
- 2024-04-09 JP JP2024062460A patent/JP7837068B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513860A5 (https=) | ||
| JP2021513859A5 (https=) | ||
| Knorr et al. | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy | |
| Dolstra et al. | Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients | |
| Becker et al. | Selection and expansion of natural killer cells for NK cell-based immunotherapy | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Linn et al. | The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies | |
| Rettinger et al. | The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells | |
| EP3188740B1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| Ye et al. | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes | |
| Linn et al. | A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission | |
| JP2014526244A5 (https=) | ||
| JP2020518289A5 (https=) | ||
| JP2024086827A5 (https=) | ||
| Todorovic et al. | Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers | |
| JP2021512903A5 (https=) | ||
| CN115282165A (zh) | 来自胎盘的自然杀伤细胞 | |
| US20170296584A1 (en) | Methods for expanding t cell populations | |
| JPWO2007105797A1 (ja) | 新規なヒトｔ細胞集団 | |
| JPWO2019165097A5 (https=) | ||
| Trujillo-Ocampo et al. | IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+ CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile | |
| Liu et al. | Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma | |
| Okas et al. | Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation | |
| Couban et al. | The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation | |
| Yee | Adoptive therapy using antigen-specific T-cell clones |